MGNX Macrogenics (MGNX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001125345
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
72
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $124.8K priced
What the filings say about MGNX
Insiders, 180 days
-$129.1K net sold
1 seller · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$580.5K
5 notices
Macrogenics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MACROGENICS INC insiders sold a net $129.1K of stock across 41 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Apr 4, 2024.
- No other insider sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP, GC, and Secretary Peters Jeffrey Stuart sold about $129.1K of MGNX under a 10b5-1 plan on Aug 19, 2026, the largest insider sale at the company since 2024; 72 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 19, 2025.
- The trade is 44.6% of the 111,000 shares held after it.
- No other insider bought within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HEIDEN WILLIAM K bought about $73.8K of MGNX on Aug 20, 2025; 72 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 82.1% of the 61,500 shares held after it.
- No other insider bought within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HEIDEN WILLIAM K bought about $76.8K of MGNX on Aug 19, 2025, the largest insider purchase at the company since 2023; 72 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.4% of the 9,532 shares held after it.
- No other insider sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, Controller & Treasurer Smith Beth Ann sold about $1.1K of MGNX on Feb 15, 2025; 72 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 6, 2024.
- The trade is 169.1% of the 3,165 shares held after it.
- No other insider sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP and General Counsel Peters Jeffrey Stuart sold about $94.9K of MGNX on Apr 4, 2024; 72 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$129.1K over 180 days
-$129.1K over 90 days
more than 54% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
72 funds bought in last quarter
more than 57% of Pharma & Biotech
Revenue
-0.3% year over year
below 57% of Pharma & Biotech
Margin
-49.9% net margin
more than 50% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.5% of the float short (float per yahoo 2026-10-26) · 10.9 days to cover · settled 2026-09-30
more than 75% of Pharma & Biotech
What changed in the last 30 days
Oct 22Former Director Karen Ferrante filed to sell $79.2K by Oct 22 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch MGNX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+19.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MGNX: institutional holders (13F)
13F holdings, latest reported quarter
5,006,752 sh
$23.1M
4,679,229 sh
$21.6M
2,656,010 sh
$12.3M
2,632,750 sh
$12.2M
2,488,252 sh
$11.5M
Congress trades in MGNX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MGNX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Karen Ferrante
Filed 2026-10-22
$79.2K
Thomas Spitznagel
Filed 2026-09-21
$65.5K
Jeffrey Peters
Filed 2026-08-19
$129.1K
Jay Siegel
Filed 2026-08-17
$175.7K
Jay Siegel
Filed 2026-08-03
$130.9K
MGNX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Wasatch Long/Short Alpha Fund
$443.7K position · as of 2026-06-30
1.2%
Wasatch Ultra Growth Fund
$5.2M position · as of 2026-06-30
1.1%
Wasatch Micro Cap Fund
$3.6M position · as of 2026-06-30
0.5%
Nomura Healthcare Fund
$1.9M position · as of 2026-06-30
0.3%
Ultra-Small Company Market Fund
$339.6K position · as of 2026-06-30
0.2%
SMALL COMPANY GROWTH PORTFOLIO
$2.0M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
24 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
10
Phase 1
4 active
6
Phase 2
1 active
2
Phase 3
0 active
1
Not applicable
0 active
5
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
IGF::OT::IGF DUAL AFFINITY RE-TARGETING MOLECULES FOR HIV-1 SUPPRESSION · 2015-09-14
$24.6M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Scott Koenig
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$6.4M
$1.8M
$2.5M
-86%
n/a
2023
$3.7M
$6.5M
$1.7M
-58%
n/a
2022
$4.6M
-$570.5K
$1.8M
-71%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $129.1K sold by insiders over 180 days, 72 funds added last quarter, $580.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MGNX financials
Revenue growth
-0.3%
XBRL, annual
Net margin
-49.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$167.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MGNX
| FY Dec 2025 | $149.5M |
| FY Dec 2024 | $150.0M |
| FY Dec 2023 | $58.7M |
| FY Dec 2022 | $151.9M |
| FY Dec 2021 | $77.4M |
| Jun 2026 | $32.8M |
| Mar 2026 | $20.8M |
| Dec 2025 | $41.2M |
| Sep 2025 | $72.8M |
| Jun 2025 | $22.2M |
| Mar 2025 | $13.2M |
| Dec 2024 | $19.4M |
| Sep 2024 | $110.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+35.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MGNX
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -78.8% |
| FY Dec 2021 | -261.0% |
| Jun 2026 | +59.4% |
| Mar 2026 | -177.0% |
| Dec 2025 | +146.5% |
| Sep 2025 | +23.1% |
| Jun 2025 | -163.0% |
| Mar 2025 | -311.1% |
| Dec 2024 | +266.0% |
| Sep 2024 | +50.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$65.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MGNX
| FY Dec 2025 | -$83.0M |
| FY Dec 2024 | -$72.1M |
| FY Dec 2023 | -$80.0M |
| FY Dec 2022 | -$90.6M |
| FY Dec 2021 | -$150.0M |
| Jun 2026 | -$41.6M |
| Mar 2026 | -$36.2M |
| Dec 2025 | $42.8M |
| Sep 2025 | -$30.6M |
| Jun 2025 | -$47.7M |
| Mar 2025 | -$47.4M |
| Dec 2024 | -$39.0M |
| Sep 2024 | $59.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity MGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt MGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+134.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MGNX
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -62.8% |
| FY Dec 2021 | -75.5% |
| Jun 2026 | +134.0% |
| Mar 2026 | +8.3% |
| Dec 2025 | -0.1% |
| Sep 2025 | -9.6% |
| Jun 2025 | +58.4% |
| Mar 2025 | +12.0% |
| Dec 2024 | -0.0% |
| Sep 2024 | -56.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+20.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MGNX
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -38.9% |
| FY Dec 2021 | -56.6% |
| Jun 2026 | +20.3% |
| Mar 2026 | +1.9% |
| Dec 2025 | -0.0% |
| Sep 2025 | -3.4% |
| Jun 2025 | +13.7% |
| Mar 2025 | +4.7% |
| Dec 2024 | -0.0% |
| Sep 2024 | -29.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital MGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed MGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | -49.3% |
| FY Dec 2023 | -71.0% |
| FY Dec 2022 | -49.3% |
| FY Dec 2021 | -68.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -55.6% |
| Jun 2025 | -48.3% |
| Mar 2025 | -55.0% |
| Dec 2024 | -49.3% |
| Sep 2024 | -43.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value MGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-47.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield MGNX
| FY Dec 2025 | -81.5% |
| FY Dec 2024 | -35.3% |
| FY Dec 2023 | -13.4% |
| FY Dec 2022 | -22.0% |
| FY Dec 2021 | -15.3% |
| Jun 2026 | -22.3% |
| Mar 2026 | -39.0% |
| Dec 2025 | -81.5% |
| Sep 2025 | -155.2% |
| Jun 2025 | -97.7% |
| Mar 2025 | -90.4% |
| Dec 2024 | -35.3% |
| Sep 2024 | -29.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $149.5M | $150.0M | $58.7M | $151.9M |
| Operating income | -$72.8M | -$110.6M | -$168.2M | -$121.4M |
| Net income | -$74.6K | -$67.0K | -$9.1K | -$119.8M |
| EPS (diluted) | n/a | n/a | -0.15 | -1.95 |
| Operating cash flow | -$81.0M | -$68.4M | -$78.2M | -$87.0M |
| Cash | $57.2M | $182.8M | $101.0M | $108.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
MGNX Stock Sonar score 5/7 axes
Find similar shapesCompareMGNX ranks highest on profitability (95th percentile) and institutional and government (57th), and lowest on insider conviction (1st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MGNX filings, in plain words
Are Macrogenics insiders buying or selling MGNX?
In the 180 days to 2026-10-28, Macrogenics insiders were net sellers, a net $129.1K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of MGNX?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $580.5K of stock; the latest, by Karen Ferrante, was filed 2026-10-22.
Read the full summary
In the 180 days to 2026-10-28, Macrogenics insiders were net sellers of MGNX, a net $129.1K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $580.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
